Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent is providing the entire workflow of target enrichment for different NGS applications such as cancer, infectious and rare diseases. including sample quality control (QC), next-generation sequencing (NGS) library prep and target enrichment, microarrays, CRISPR, PCR/qPCR, bioreagents, and data analysis solutions from interpretation reporting. Furthermore, with the extensive cancer diagnostic and pathology know-how of Agilent Dako, built on more than 50 years of experience, our business of antibodies & assay solutions has established lasting partnerships worldwide with partnering companies, ranging from large multinationals to smaller manufacturers and commercial laboratories specializing in the fields of in vitro diagnostics, biotechnology and pharmaceuticals. Besides the development of companion diagnostic for novel personalized therapy in cancer treatment, collaboration partners also benefit from the high level of familiarity of the Agilent Pathology-portfolio in routine diagnostic.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.
Boston Healthcare believes that meaningful and sustained innovation in healthcare depends on identifying optimal pathways to commercial success.
Boston Healthcare is a global consulting firm focused on enabling companies to derive optimal value from innovative products and services that have the potential to transform standards of care and significantly improve health outcomes. We have aligned our services and expertise to assure that the innovators reshaping healthcare are rewarded for their efforts and commitment, and we tailor our approach to the product and specific characteristics of each geographic market.
Headquartered in Tucson, Arizona, HTG is focused on accelerating precision medicine – from diagnosis to treatment – by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas. HTG’s proprietary extraction-free RNA expression technology simplifies and automates complex, highly multiplexed gene expression profiling from solid and (biofluid) liquid samples, even when limited by amount and quality. HTG’s transcriptome and targeted panels are designed to enable biomarker profile assessment and gene signature development associated with disease state, treatment response and outcome.
Precision Antibody prides itself in developing application-specific antibodies with high specificity and sensitivity. In the field of biomarkers, the specificity and sensitivity of reagents are key performance characteristics for a successful assay development necessary for clinical application. With over 20 years of experience and expertise, Precision Antibody (PA) understands these challenges, offering a “one-stop shop” for many clients needing comprehensive application-specific antibody development services, from initial antigen design and immunization to antibody development, characterization, sequencing, and purification. Thanks to our ability to deliver antibodies that work in the intended assay in 60 days, PA has become a preferred vendor for many major pharmaceutical, biotech, and diagnostic companies, including many academic and government institutions, to fulfill their therapeutic and diagnostic needs.
Cellular Technology Limited (CTL) specializes in cell-mediated immunity as an all-in-one solution provider for standardized immune monitoring. We offer a comprehensive platform of instrumentation, reagents and services including our industry leading Analyzers, the largest portfolio of ELISPOT/FluoroSpot kits, an extensive library of HLA-typed cryopreserved PBMC, CD8/CD4 positive antigen controls, novel whole-well image-based cytotoxicity assays and a CLIA-certified Contract Laboratory offering services including: cryopreservation of samples, GLP compliant testing (using ELISPOT, ELISA, NAb, FACS), and customized assay development/validation.
Burning Rock Dx (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of 1) NGS-based therapy selection testing for late-stage cancer patients, 2) Global pharmaceutical services on biomarker detection and companion diagnostics developing, and 3) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage
Burning Rock focuses on providing comprehensive cancer genomic solutions for pharmaceutical companies from biomarker discovery to commercialization. Powered by our multimodal central lab testing, integrated companion diagnostic development and commercialization, Burning Rock facilitates the entire process of anti-cancer drug development.
